Impact of Obesity on Survival Rates and Chemotherapy Efficacy in Stage IV Colorectal Cancer: A Retrospective Analysis - Summary - MDSpire

Impact of Obesity on Survival Rates and Chemotherapy Efficacy in Stage IV Colorectal Cancer: A Retrospective Analysis

  • By

  • Catherine G. Tran

  • Carine Dornbush

  • Braden S. Jensen

  • Sarah L. Mott

  • Elise E. H. Fannon

  • Austin C. Stark

  • Meghan E. Mali

  • Daniel J. Berg

  • Erin E. Talbert

  • Carlos H. F. Chan

  • February 5, 2026

  • 0 min

Share

Objective:

To determine the association between BMI, survival outcomes, and chemotherapy duration in patients with stage IV colorectal cancer (CRC).

Key Findings:
  • Median overall survival (OS) was 20.9 months for the cohort.
  • Median OS for normal weight (NW), overweight, and obese patients was 18.2, 22.3, and 24.0 months, respectively.
  • Obese patients had a higher likelihood of N2 disease compared to NW and overweight patients.
  • After adjustment, NW and overweight patients had a higher risk of death compared to obese patients.
Interpretation:

Obesity may be associated with improved survival outcomes in stage IV CRC, contradicting previous assumptions about BMI as a negative prognostic factor.

Limitations:
  • Single institution study may limit generalizability.
  • Retrospective design may introduce biases.
Conclusion:

The study suggests that obesity may confer a survival advantage in stage IV CRC, challenging the traditional view of BMI as a negative prognostic factor.

Original Source(s)

Related Content